Department of Hematology, Odense University Hospital, Denmark.
Department of Pathology, Odense University Hospital, Denmark.
J Low Genit Tract Dis. 2022 Oct 1;26(4):287-292. doi: 10.1097/LGT.0000000000000693.
The purpose of this study was to assess if cytology can be omitted in the follow-up after treatment for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and if human papillomavirus (HPV) test can be used alone as test of cure (TOC) after stratifying for resection margins.
In this retrospective register-based study, women who had a conization performed in Denmark between January 1 and December 31, 2013, were included. Histology, cytology, and HPV test results were obtained from The Danish Pathology Data Bank for a 3-year follow-up.
A total of 5,174 women were included, of whom 6.1% (318/5,174) had histological residual/recurrent disease in the follow-up period. In the group with free margins, 2.6% (73/2,780) had residual/recurrent disease in contrast to 10.2% (245/2,394) in the group with involved margins. In the group with free resection margins and negative HPV test results, residual/recurrent disease was found in 0.5% (13/2,780) compared with 0.3% (9/2,780) in the group with negative HPV test results and normal cytology at 6 months' follow-up. Based on margin status and HPV test result as follow-up, the sensitivity, specificity, and positive and negative predictive values were 95.9%, 43.2%, 10.0%, and 99.4% respectively, and for combined testing (margin status, HPV, and cytology), 97.2%, 41.2%, 9.8%, and 99.6%, respectively.
Using the HPV test at the first post-treatment control as TOC for cervical intraepithelial neoplasia grade 2 or worse after stratifying for resection margins in cone resections yields an equally high sensitivity and negative predictive value as cotesting with cytology. We suggest that women with free resection margins return to the routine screening program after negative HPV test result as TOC at 6 months.
本研究旨在评估在 CIN2+治疗后是否可以省略细胞学随访,以及在分层切除边缘后是否可以单独使用人乳头瘤病毒(HPV)检测作为治愈测试(TOC)。
本回顾性基于登记的研究纳入了 2013 年 1 月 1 日至 12 月 31 日期间在丹麦接受子宫颈锥形切除术的女性。从丹麦病理学数据库获得了 3 年随访期间的组织学、细胞学和 HPV 检测结果。
共纳入 5174 名女性,其中 6.1%(318/5174)在随访期间有组织学残留/复发疾病。在边缘无病变组中,2.6%(73/2780)有残留/复发疾病,而在边缘有病变组中,10.2%(245/2394)有残留/复发疾病。在边缘无病变且 HPV 检测结果阴性的组中,发现残留/复发疾病的比例为 0.5%(13/2780),而在 6 个月随访时 HPV 检测结果阴性且细胞学正常的组中,这一比例为 0.3%(9/2780)。基于边缘状态和 HPV 检测结果作为随访方法,其敏感性、特异性、阳性预测值和阴性预测值分别为 95.9%、43.2%、10.0%和 99.4%,而联合检测(边缘状态、HPV 和细胞学)的敏感性、特异性、阳性预测值和阴性预测值分别为 97.2%、41.2%、9.8%和 99.6%。
在锥形切除术分层切除边缘后,使用 HPV 检测作为 CIN2+治疗后的首次治疗后控制 TOC,其敏感性和阴性预测值与细胞学联合检测相当。我们建议,对于边缘无病变且 HPV 检测结果阴性的女性,在 6 个月时作为 TOC 进行 HPV 检测阴性后,可回归常规筛查计划。